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Cancer stem cells (CSCs) are tumor cells that have the principal properties of self-renewal, clonal tumor initi-
ation capacity, and clonal long-term repopulation potential. CSCs reside in niches, which are anatomically
distinct regions within the tumor microenvironment. These niches maintain the principle properties of
CSCs, preserve their phenotypic plasticity, protect them from the immune system, and facilitate their meta-
static potential. In this perspective, we focus on the CSC niche and discuss its contribution to tumor initiation
and progression. Since CSCs survive many commonly employed cancer therapies, we examine the pros-
pects of targeting the niche components as preferable therapeutic targets.Introduction
Cancer cells within individual tumors often exist in distinct
phenotypic states that differ in functional attributes. Within this
tumor heterogeneity, cancer stem cells (CSCs) are tumor cells
that have the principal properties of self-renewal, clonal tumor
initiation capacity, and clonal long-term repopulation potential
(Clarke et al., 2006; Nguyen et al., 2012). They also display plas-
ticity by reversibly transitioning between stem and non-stem cell
states. CSCs have the ability to evade cell death and metasta-
size, although they may stay dormant for long periods of time
(Kreso et al., 2013). Both experimental models and clinical
studies indicate that CSCs survive many commonly employed
cancer therapeutics (Kreso and Dick, 2014).
As is the case for normal stem cells, CSCs are believed to
reside in niches. Niches are specialized microenvironments
that regulate adult stem cell fate by providing cues in the form
of both cell-cell contacts and secreted factors. Niches have
been identified for mammalian stem cells in various epithelial tis-
sues, such as the intestine as well as in neural, epidermal, and
hematopoietic systems (Voog and Jones, 2010). Normal niches
are comprised of fibroblastic cells, immune cells, endothelial
and perivascular cells or their progenitors, extracellular matrix
(ECM) components, and networks of cytokines and growth fac-
tors (Korkaya et al., 2011). The CSC niche itself is a part of the
tumor microenvironment (TME), which is a collective term for
the adjacent stroma along with the normal counterparts of the
tumorigenic cells (Hanahan and Coussens, 2012). Non-CSC tu-
mor cells are also part of the CSC niche. During the progression
of tumors to amoremalignant state, the CSC state in the primary
tumor depends crucially on the TME and potentially on the CSC
niches within it (Fessler et al., 2013). In this perspective, we focus
on the emerging field of the CSC niche, which is yet to be fully
elucidated. We critically discuss the contribution of the niche
to tumor initiation and progression and examine the prospects
of targeting the niche for cancer therapy. Although we focus on
conceptual similarities between various niches, it is important
to note that glioblastomas, melanomas, and especially hemato-poietic cancers may have a very different pattern of regulation
than those in the more common carcinomas. One major differ-
ence is that hematopoietic cells are inherently mobile, whereas
epithelial cells need to gain mobility de novo to metastasize.
Models of Tumorigenesis, CSC Plasticity, and the Role
of the CSC Niche
It has long been postulated that intratumoral heterogeneity con-
tributes to disease progression, impacts therapeutic efficacy,
and therefore affects patient survival (Hanahan and Weinberg,
2011). The TME contributes to tumor heterogeneity along with
genetic diversity and epigenetic modifications within tumor cells
(Kreso andDick, 2014). Twomodels, hierarchical and stochastic,
have been used to understand tumor progression and heteroge-
neity. Although they differentially consider the weight that CSCs
and their niches carry in driving a particular tumor, these two
models are not mutually exclusive, and the concept of cellular
plasticity unifies them into one model.
The Hierarchical Model
The hierarchical model designatesmalignant tumor-propagating
cells as CSCs (Figure 1). It relies on the paradigm that CSCs
represent a biologically distinct subset within the total cancer
cell population. According to this model, carcinogenesis occurs
when a stem cell escapes regulation and gives rise to a stem-
cell-like counterpart, a CSC. CSCs represent a distinct popula-
tion that can be isolated from the remainder of the tumor cells.
They can self-renew their own population and have long-term
clone-propagating capacity so they can generate short-lived
progeny with self-limited proliferative capacity (Kreso and Dick,
2014). Due to the self-renewal capacity, CSCs represent the
unit of selection in a tumor, while any of the other cells lead to
clonal exhaustion (Greaves, 2013). The clinical implication from
this model is that only complete eradication of all CSCs will
eliminate the possibility of relapse. The hierarchical model was
first demonstrated in acute myeloid leukemia, in which a subset
of leukemia cells expressed stem cell markers and harbored
the potential of self-renewal, propagation, and differentiationCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 225
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Figure 1. Models of Carcinogenesis
Models are exemplified for an epithelial tissue.
Hierarchical model of carcinogenesis: Normal stem
cells have limited proliferative capacity and give rise
to progenitor cells that proliferate and differentiate
into various types of cells. If a normal stem cell es-
capes regulation, it becomes a cancer stem cell,
which can self-renew and produce cancer progen-
itor cells. If a normal progenitor cell escapes regu-
lation, it becomes cancer progenitor cells, which
can give rise to poorly differentiated cells. If those
cells are generated from different types of cancer
progenitor cells, they might form different subtypes
of tumors with limited proliferative capacity. Due to
plasticity (red arrows), the progenitor cells and
some of the differentiated cells can de-differentiate
to become CSCs again. Either CSCs from normal
stem cells or from cancer progenitor cells initiate
and sustain aggressive tumor growth, and the cells-
of-origin for these two types of tumors are either
CSCs (blue arrow) or cancer progenitor cells (purple
arrow), respectively.
Stochastic model of carcinogenesis: Healthy
epithelial cells develop an oncogenic mutation
(yellow strikes) that forms hyperplasia. Some of the
hyperplastic cells can become the cells-of-origin
developing additional oncogenic mutations and
transform into tumor cells. Under multiple clonal
evolutions (colonies shown with various colors),
aggressive tumors can form. Some mutations can
lead to a stem-cell-like permissive epigenome and
thus create cancer progenitor cells. This process
reconciles the stochastic model with the hierarchi-
cal model. However, if the hyperplastic cells
develop non-oncogenic mutations (green strikes),
they will not transform into tumor cells, although
they may continue to proliferate. If healthy epithelial
cells initially undergo non-oncogenic mutations
(green strikes), they can overcome such mutations
and maintain a healthy tissue.
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in breast cancer, as theywere particularly efficient in establishing
tumors upon their isolation from the tumor bulk and their Trans-
plantation into mice (Al-Hajj et al., 2003). Since then, the exis-
tence of CSCs has been shown in various cancers including
various hematopoietic, head and neck, prostate, lung, brain, co-
lon, skin, and pancreatic cancers, as well as in sarcomas (re-
viewed in Kreso and Dick, 2014; Oskarsson et al., 2014).
Given that cancer is characterized by proliferation and ex-
pansion yielding tissues that do not anatomically or functionally
resemble the original organ, self-renewal, proliferation, and dif-
ferentiation are most likely deregulated in CSCs. Indeed, the ma-
jority of evidence indicates that CSCs in most solid tumors lack
true multipotency and asymmetric cell division and can only
differentiate into a single type of descendant cancer cell that is
unable to generate an entire array of lineages (Kreso and Dick,226 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.2014). Consequently, some investigators
have advocated the use of the term ‘‘tu-
mor-initiating cell’’ (TIC), rather than
CSC, to describe the subset of cells with
tumorigenic potential (Hill and Perris,
2007). Although the TIC and the CSC
have been used interchangeably, the
TIC more appropriately denotes the cellof origin. Importantly, the hierarchical model assumes that the
CSC is the cell of origin (i.e., the first abnormal cell that initiates
the tumor). However, and as explained later, due to cellular plas-
ticity, the cell of origin is not necessarily the CSC—that is, the
cellular subset within the tumor that uniquely sustains primary
and metastatic tumor growth. Therefore, the phenotype and
characteristic gene-expression patterns of the cell of origin
may differ substantially from that of the CSC (Chaffer and Wein-
berg, 2015).
According to the hierarchical model, the sameCSCor different
sets of CSCs can give rise to different cancer subtypes within a
certain organ or tissue (Visvader and Lindeman, 2008), which re-
sults in the cellular heterogeneity of tumors. Those distinct sub-
clones develop in a hierarchical fashion with their own CSCs.
However, the major limitation of this model is that it conceptually
precludes the interchange between differentiated and stem-like
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accommodates the possibility that CSCs, like their normal coun-
terparts, may retain responsiveness to and even dependence on
external cues to elicit their intrinsically determined potentialities
for survival, growth, and differentiation, irrespective of how per-
turbed the process of differentiation may be.
The Stochastic Model
The stochastic model states that every cell within a tumor is
equally likely to be the cell of origin and facilitate tumor initiation
and progression (Figure 1). The variable activities of tumor cells
are only partially determined by the environment in which the cells
are found, but rather are determined by some stochastically vary-
ing intrinsic factors (Quail et al., 2012). The stochasticmodel relies
on the premise that cancer is a disease defined by hyperprolifer-
ation and sequential acquisition of genetic mutations in cell-cycle
genes that contribute to subsequent clonal expansions in an
otherwise relatively quiescent normal adult somatic cell. Indeed,
advanced genome sequencing has demonstrated that cancer
within a single patient is a heterogeneous mixture of genetically
distinct sub-clones that arise through branching evolution
(Greaves and Maley, 2012; Burrell et al., 2013) and seed different
parts of a single tumor (Gerlinger et al., 2012). Althoughmutational
burden is highly variable across tumor types (Lawrence et al.,
2013), a typical tumor contains two to eight driver mutations
that regulate three core cellular processes: cell fate, cell survival,
and genomemaintenance (Vogelstein et al., 2013). Whole-exome
and whole-genome sequencing of thousands of tumors show
that in the same tumor type there is substantial variation in driver
mutations and the same drivermutations canoccur in different tu-
mor types, suggesting that the same pathways can be active in
different tumors (Alexandrov et al., 2013; Kandoth et al., 2013).
Several tumor types appear to adhere to the stochastic model;
good examples are some colorectal cancers (Vogelstein et al.,
1988) and B cell lymphoblastic leukemias (Williams et al.,
2007). However, this model focuses on genetic heterogeneity
without considering that individual cells within genetically homo-
geneous sub-clones might still exhibit phenotypic variations due
to different microenvironmental cues and therefore may not ac-
count for the heterogeneity in tumor initiation capacity.
Cellular Plasticity Reconciles the Hierarchical and
Stochastic Theories into One Model
Phenotypic plasticity characterizes a population of cancer cells
that have the capacity to interconvert between differentiated
and stem-like states, through a continuum of cell fate specifica-
tions (Quail et al., 2012). Based on this characteristic, the hierar-
chical versus stochastic models is a false dichotomy, as hierar-
chically organized cell populations are more transitory between
states than previously imagined and stochastic events are able
to generate novel, hierarchically organized cell populations.
Thus, depending on the genotype and the microenvironmental
signals experienced by transit-amplifying/progenitor cells, at
least in epithelial tissues, such cells may dedifferentiate and
thereby enter back into the CSC pool to regain long-term tumor
repopulation capacity (Chaffer and Weinberg, 2015). This dedif-
ferentiation capacity may be either inherited (hierarchical theory)
or acquired via mutations that lead to a stem-cell-like permissive
epigenome (stochastic theory).
Indeed, p53 inhibition and Human telomerase reverse tran-
scriptase (hTERT) activation (Hahn et al., 1999; Stewart et al.,2002; Hong et al., 2009) or the aberrant acquisition of stem-
cell-associated factors such as Neurogenic locus notch homo-
log (NODAL), NOTCH, and Wingless-type MMTV integration
site family (WNT) proteins facilitates such phenotypic plasticity.
Moreover, the concept of cellular plasticity suggests that sym-
metrical cell division may not be as necessary to enlarge the
CSC pool and could be secondary to asymmetrical division as
progenitor cells, asymmetrically divided from CSCs, are more
proliferative and can convert back to CSCs. The fact that mela-
noma, breast, prostate, ovarian, and lung cancer cells are all able
to alter their gene expression to resemble cell types that are not
part of their original lineage (Quail et al., 2012) exemplifies cancer
cell plasticity that enables cancer cells to gain/lose stem cell
properties (Shirakawa et al., 2002; Passalidou et al., 2002; Lim
et al., 2009). Since regaining tumor-initiating capacity is poten-
tially possible (Gupta et al., 2011), it is essential to understand
how the TME and the CSC niche within it promote CSC pheno-
types.
CSC Assays Should Consider Niche Contributions
In general, stem cell markers (Table S1) and transcriptional sig-
natures specific to CSCs functionally correlate with aggressive
behavior and are highly predictive of overall patient survival.
These clinical data suggest that CSCsmay be critical therapeutic
targets (Suva` et al., 2009; Karnoub et al., 2007). However, it
became increasingly clear that the frequency of CSCs could
vary dramatically between tumor types and also between tumors
of the same origin (Visvader and Lindeman, 2008). A related
problem is that the variability in the frequency and identity of
tumorigenic cells between patients shows that markers identi-
fied in one tumor cannot be assumed to distinguish CSCs in
other tumors or in other contexts (Ricardo et al., 2011; Lopez
et al., 2005; Rocco et al., 2012).
Many theoretical and experimental caveats to the CSC model
have remained unexplored, largely due to technological chal-
lenges. The gold standardmeasure of a stem cell is maintenance
of long-term clonal growth in functional repopulation assays,
originally used for studies of the hematopoietic system. Until
recently, most CSC studies utilized the transplantation assay
to prove the existence of CSCs for a particular tumor. The
markers for CSCs are primarily chosen as robust and heteroge-
neously expressed cell surface markers that allow the faithful
flow cytometric sorting of marker-positive and -negative subsets
in a certain tumor type. These subsets are transplanted into
immunodeficient mice by limiting dilution, after which tumor
growth is scoredwithin several weeks ormonths. Different tumor
initiation capacities between cell subsets are then interpreted as
evidence for the presence of CSCs in the primary tumor (Clevers,
2011). Self-renewal is further demonstrated by the ability to
establish or maintain the tumor clone in serial transplantation
assays at clonal cell doses and give rise to daughter cells that
possess limited proliferative capacity (Clarke et al., 2006). Often
no clear morphological or cell-cycle distinction is obvious
between the tumorigenic and non-tumorigenic cancer cells (Al-
Hajj et al., 2003), and yet the tumors seem to be organized hier-
archically when tested functionally.
There are several problems with the transplantation assays
commonly used to identify CSC activity. The sorted and trans-
planted human cancer cells are challenged by various experi-
mental manipulations and subsequently end up in a contextCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 227
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The new recipient microenvironments can then differentially in-
fluence the transplanted cells based on time, species barrier,
host strain, developmental stages, and even gender (LaBarge,
2010). Thus, the frequent need for the inoculation of 105 cells
in transplantation experiments to allow efficient tumor engraft-
ment may not be indicative of a rare TIC but rather may represent
the inability to create the proper niche. On the other hand,
extremely immunodeficient models can support tumor initiation
from the majority of tumor cells, even those not associated
with stem cell markers, as shown for patient-derived melanoma
cells (Quintana et al., 2008). It is worth noting that melanomamay
represent a unique cell type that is particularly poised to enter
into the CSC state, since melanocytes may be naturally inclined
to stem cell states that enhance a migratory phenotype (Quin-
tana et al., 2012). Furthermore, transplantation assays provide
only a snapshot of the state of cancer cells at the time of tumor
removal and basically ignore CSC plasticity (Kreso and Dick,
2014). Therefore, the host microenvironments in those assays
may distort the original tumorigenic potential and frequently
select for the most robust TICs that can grow due to multiple
long treatments and loss of their native TME (Kreso and Dick,
2014). Conversely, some cells with tumorigenic potential do
not contribute to tumor growth, because they are in a non-
permissive environment or eliminated by immune effector cells,
but will do so upon transplantation.
To date, most CSC markers are not selected based on a deep
understanding of the underlying stem cell biology of the relevant
tissue from which the cancer originates, since developmental hi-
erarchy is still poorly characterized in most tissues that develop
solid cancers. Moreover, only very few CSC markers are
currently available for various solid tumors (Clevers, 2011). In
some cases, the markers used to rigorously demonstrate the ex-
istence of CSCs in a particular cancer subtype were very specific
for that cancer, as was shown for breast cancer cells (Clarke
et al., 2006). The fact that the markers used are not widely appli-
cable to other types of cancers does not weaken the conclusion
of such studies. Nevertheless, these CSC markers only strongly
enrich (even by two orders of magnitude) for CSCs within bulk
populations of cancer cells, but there is no evidence that, in
such enriched populations, the CSCs exist in a pure state rather
than constituting a subset of the cells with a greatly heightened
ability to initiate tumors. Moreover, at the time of transplantation,
these cells may not necessarily possess CSC capabilities, but
rather may gain them upon transplantation, which may not
have happened within their native niches.
To separate between the inherent plasticity of CSCs and/or
the plasticity induced or inferred by the experimental limita-
tions discussed above, it will be crucial to continue and opti-
mize transplantation assays potentially by development of
more immune-deficient recipient mice and humanizing these
with human TME and/or growth factors (Rongvaux et al.,
2013), to estimate as accurately as possible the spectrum of
cancer cells that retain the potential to contribute to tumor
growth (Meacham and Morrison, 2013). Specifically, it was
recently shown that the growth of dormant cancer sub-clones
could be solely induced by microenvironmental changes
caused by a sub-population of cancer cells that does not
display the higher fitness commonly associated with CSCs228 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.(Marusyk et al., 2014). In addition, co-transplantation with stro-
mal cells from myeloproliferative neoplasms enabled engraft-
ment and expansion of neoplastic cells that was otherwise
not as successful (Medyouf et al., 2014).
Given that the major limitation of transplantation assays is that
they cannot reveal the actual fate of the transplanted cell in its
original tissue or tumor (Shackleton et al., 2009), it is of central
importance to develop assays that can visualize and localize
CSCs and their function within the primary tumor in situ. Live
imaging methodologies could bring us closer to unraveling
whether, in a particular niche and at a particular point in time,
the cell visualized is indeed a CSC rather than a representative
of a cell population that is only enriched in CSCs. It would allow
us to examinewhether, under a specificmicroenvironment, a cell
is able to proliferate and produce progeny/various clones. Inte-
gration of genomic and functional properties of CSCs that have
yet to be extensively utilized could further facilitate the identifica-
tion of single, definitive marker genes for CSCs of a particular
cancer. Based on such markers, knock-in mouse models or
viral-tagging strategies may facilitate genetic lineage tracing
(Kreso and Dick, 2014). Lineage tracing or fate-mapping assays
are indeed a complementary measure for the long-term clonal
growth of stem cells. These assess the actual fate of tumor cells
in a particular context, frequently the native tumor environment
rather than the potential of what these cells can do under permis-
sive conditions. Yet, lineage-tracing experiments may also pro-
vide only limited support for the CSC model. Although intestinal
adenomas were shown to be hierarchically organized by
Leucine-rich repeat-containing G protein-coupled receptor 5
(Lgr5)+ CSCs, both Lgr5 cells and Lgr5+ cells can act as the
cell of origin via WNT-pathway activation, as exhibited by fate
mapping (Schwitalla et al., 2013). This raises the question of
whether adenomas that exhibit hierarchical organization lose it
after they progress to malignancies. Although brain tumors
may be different from carcinomas, similar concerns have been
shown for markers such as CD133 in brain tumors (Meacham
and Morrison, 2013). Ultimately, it will be necessary to integrate
the data from both transplantation studies and fate-mapping
studies of significant numbers of human and mouse tumors to
understand the biological diversity. Additionally, the selective
ablation of genetically defined subsets of cells (Plaks et al.,
2013a) can test which tumor cells are fated to contribute to tumor
growth or progression in the native tumor environment. Collec-
tively, combining in vivo models and ex vivo systems discussed
should prove useful in systematically characterizing the intricate
molecular language of cell-cell communication in the CSC niche.
Cross Talk between CSCs and Their Niches
Niches are anatomically distinct microenvironments within the
overall TME. Cells within the CSC niche produce factors that
stimulate CSC self-renewal, induce angiogenesis, and recruit
immune and other stromal cells that secrete additional factors
to promote tumor cell invasion and metastasis, as reviewed in
Oskarsson et al. (2014) and Ye et al., (2014) and summarized
below (Figures 2 and 3).
Cancer-Associated Fibroblasts
There is evidence pointing to factors produced by CSCs and
endothelial cells (ECs) in the TME that can transform normal
fibroblasts into cancer-associated fibroblasts (CAFs) (reviewed
•Self-renew
•Plasticity
•Dormancy
•Metastasis
•Therapeutic resistance
CSC
Stemness
CSCMSC
NF-κB EMT
TGF-β
HIF-1α
cMyc
WNT/
NOTCH
Germlin 1
IL6
CXCL12
IL8
TAM
IL4
TH2
GM-CSF
G-CSF
M-CSF
TNF-α
Tumor cell
ROS
Hypoxia
Angiogenesis
NK cell
TReg
Endothelial cell
VEGF-A
NO
CXCL12
CAF
TNC
HGF
MMP2/9
MMP3
MMP10ECM 
remodeling
Immuno-
surveillance
Anti-tumor
DC
MDSC
VEGF-A
DCTAN
CD8+ T cell
Figure 2. TheMolecular andCellular Basis of
the Cross Talk between CSCs and Their
Niches
CSCs are metastatic cancer cells that can self-
renew. Their plasticity and dormancy correlates
with their therapeutic resistance. By secreting
CXCL12, IL6, and IL8, MSCs promote cancer cell
stemness through upregulating NF-kB while CSCs
secrete IL6 to attract more MSCs. MSCs also pro-
duce the antagonist, Gremlin 1, to promote the
undifferentiated state. Surrounding tumor cells
produce IL4 to accumulate TH2, which produces
TNFa to upregulate the NF-kB signaling pathway
and facilitates a pro-TME. In such a microenviron-
ment, tumor cells produce M-CSF, Granulocyte
macrophage colony-stimulating factor (GM-CSF),
and G-CSF to induce expansion of TAMs, MDSCs,
TANs, and DCs. TAM produces TNFa and TGF-b to
promote NF-kB-dependent or TGF-b-dependent
EMT and thus enhance CSC plasticity. TGF-b can
also directly interact with NF-kB signaling path-
ways to further enhance cancer cell stemness. In
addition, TGF-b produced by TAMs accumulates
Treg cells. TAM, TReg, and the hypoxic environment
inhibit immunosurveillance by inhibiting CD8+ T cell
and NK cell cytotoxicity as well as macrophage
phagocytosis. A subset of anti-tumor stimulatory
DCs necessary for T-cell-mediated tumor rejection
is kept away from the niche. Furthermore, hypoxia
increases ROS, which promotes cell survival and
induces EMT through the TGF-b signaling pathway.
Both hypoxia and ROS induce CSCs to express
HIF-1a, directly promoting EMT.Moreover, hypoxia
also inhibits cell proliferation by downregulating c-
Myc expression, and enhancing stemness. Hypoxia further promotes cancer cell stemness by promoting an undifferentiated state through TGF-b the WNT
signaling pathway. CSCs and CAFs produce CXCL12 to promote angiogenesis, and hypoxia causes both CSCs and ECs to produce VEGF, which further induces
angiogenesis. ECs promote self-renewal of CSCs by direct cell–cell contact or by nitric oxide (NO) production via the NOTCH signaling pathway. CAFs produce
TNC and HGF to enhance WNT and NOTCH signaling for CSC maintenance. CAFs also produce MMP2, 3, and 9. Along with the MMP10 produced by CSCs,
these MMPs promote ECM degradation and remodeling, which enhances EMT and the CSC state. Of note, this figure does not provide spatial information as to
the exact localization of CSCs in respect to niche cells.
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fibroblasts, CAFs have increased proliferation, enhanced
ECM production, and unique cytokine secretion such as
CXCL12, vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), and hepatocyte growth factor
(HGF) (Junttila and de Sauvage, 2013). CAFs (as well as other
cells within the niche) stimulate stemness via activation of the
WNT and NOTCH pathways. Canonical WNT is a major pathway
that regulates CSCs and induces stemness in colon and other
cancers (Vermeulen et al., 2010; He et al., 2004). Alternatively,
epithelial non-stem cells can re-express stem cell markers
upon WNT activation and can ‘‘dedifferentiate’’ to TICs (Schwi-
talla et al., 2013). NOTCH signaling has also been implicated in
stem cell maintenance and cell-fate decisions (Quail et al.,
2012). NOTCH prevents cells from responding to differentiation
cues coming from their immediate environment (Milner and
Bigas, 1999). In breast and prostate cancers, NOTCH receptors
tend to be overexpressed, and their ligand expression correlates
with aggressive phenotypes (Weijzen et al., 2002; Liu et al.,
2006). The interplay of the WNT and NOTCH signaling with other
pathways like bone morphogenic protein (BMP) (see below) and
Hedgehog signaling pathways determines the differentiation
state of cells (Fessler et al., 2013).
Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are multipotent stromal cells
that have been implicated in multiple mechanisms promotingcancer cell proliferation and metastasis, fostering angiogenesis,
and generating an immunosuppressive microenvironment
(Cuiffo and Karnoub, 2012; Nishimura et al., 2012). They provide
an advantageous TME for the restoration of CSCs, as they
secrete a variety of cytokines that have both paracrine and
autocrine functions in the tumor milieu. MSCs can promote
cancer stemness through Nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) pathway by secreting
CXCL12, interleukin (IL) 6, and IL8 (Cabarcas et al., 2011). More-
over, MSCs can stimulate tumor progression by producing the
BMP antagonist Gremlin 1 to promote the undifferentiated state
(Davis et al., 2015). Furthermore, MSCs can cause elevatedmiR-
199a expression in breast cancer cells, which leads to aberrant
expression of a set of interrelated microRNAs and suppressed
Forkhead box protein P2 (FOXP2) expression, providing tumor
cells with CSC properties (Cuiffo et al., 2014).
Inflammatory Cells
Currently, one of the areas of greatest interest is the role of the
CSC niche in modulating the level of tumor immunity. The TME
is characterized by chronic inflammation, which stimulates tu-
mor cell proliferation and metastasis (Cabarcas et al., 2011).
To evade immune surveillance, and thus enable tumor progres-
sion, the nichemust immunosuppress the cytotoxic function and
infiltration of natural killer cells (NKs) and CD8+ T cells (Kitamura
et al., 2015; Casbon et al., 2015). For example, it was recently
shown that a rare sub-population of anti-tumor CD103+ dendriticCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 229
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Figure 3. CSC Niches in the Primary Tumor
and Metastasis
In the primary tumor, hypoxia develops within the
tumor mass due to impaired vascularization, and
ROS is increased. Both hypoxia and ROS upregulate
the CSC stress signaling pathways to enhance can-
cer cell survival and maintain cancer cell stemness.
At the same time, MSCs and CSCs produce angio-
genic factors to stimulate angiogenesis. In the pri-
mary tumor, various chemokines and cytokines are
secreted to recruit MDSCs, TAMs, and TANs. These
pro-tumorigenic and pro-metastatic cells suppress
the cytotoxic functions of NK cells and CD8+ T cells
and inhibit immunosurveillance. Treg cells are accu-
mulated by TAMs to further downregulate T cell
cytotoxicity. TAMs, CAFs, newly generated blood
vessels, and other stromal cells accumulate at the
invasive front where CAFs secrete M-CSF to turn on
TAMs’ pro-angiogenic switch. TAMs suppress anti-
angiogenic factor expression and secrete VEGF-A
and WNT to promote angiogenesis. CAF-derived
CXCL12 triggers the EGF-M-CSF loop in which
cancer cells stimulate TAMs to produce EGF by
secretingM-CSFwhile the activatedEGF receptor on
CSCs increases their invasiveness. By physically
contacting with the platelets, CSCs undergo EMT
and becomeMetSC. Also at the invasive front, WNT,
NOTCH, TNF-a, TGF-b, and other cytokines
secreted by tumor stroma support the survival of
MetSCs. Meanwhile, TAMs and CSCs release exo-
somes and factors to establish the pre-metastatic
niches for the survival of arriving tumor cells. Exo-
somes also facilitateMDR in tumor cells. In the blood
vessels, platelets surroundand preventMetSCs from
dying in the harsh and foreign environment. Clusters
of tumor cells in the blood vessels secrete M-CSF
and EGF family members to direct macrophage and
MetSCs to the sites of metastasis. After successful
extravasation and seeding of metastatic niches,
MetSCs potentially undergo MET to become CSCs,
which can become dormant or grow metastases in
three types of metastatic niche sites.
The CSCs can hijack normal stem cell niches es-
tablished by MSCs. The normal stem cell niche has
various factors like TGF-b and various cells to
maintain the stemness of CSCs and support their
survival. In the niche, CSCs can upregulate EMT
pathways in the surrounding nontumorigenic cells
and transform them into CSCs to further support the
CSCs to colonize the new niche.
Primary CSCs can also manipulate distant tissue
niches to create a metastatic niche for their future arrival. The primary tumor sends off VEGF-A, TGF-b, TNF-a, and LOX, which induce chemotactic protein
S100A expression and ECM remodeling in the metastatic sites, which creates the pre-metastatic niche. Newly formed blood vessels express fibronectin and
VCAM to attract IMs to secrete MMPs for metastatic growth. In the niche, integrins and NETs facilitate the migration and arrival of CSCs, which is maintained by
periostin and TNC upregulation. Meanwhile, LOX and S100A actively recruit MDSCs to promote metastatic growth.
CSCs initiate their metastatic outgrowth around blood capillaries created by perivascular niches enriched in angiocrine factors like VEGF-A. Surrounding TANs
also potentially enhance MetSCs settlement by producing NETs. As the niche is established, CSCs recruit TAMs, CAFs, and other stromal cells to establish the
paracrine loops to supply CSCs with TNF-a, TGF-b, and ILs for CSCmaintenance. At the meantime, the surrounding stromal cells secrete MMPs and cathepsins
to further break down the ECM, which in turn releases TGF-b and various growth factors like VEGF-A, to allow tumor expansion.
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masked from tumor antigens by other tolerizing antigen-present-
ing myeloid cell populations (Broz et al., 2014). Numerous
cell types recruited by chemokines and cytokines that are
secreted by cancer cells contribute to this immunosuppres-
sion, which include tumor-associated macrophages (TAMs),
tumor-associated neutrophils (TANs), and a population function-
ally identified as myeloid-derived suppressor cells (MDSCs).
TAMs secrete Transforming growth factor beta (TGF-b), which
recruits T regulatory cells (Tregs) that also participate in immuno-
suppression (Chanmee et al., 2014). MDSCs are a heteroge-
neous population of cells from monocytic and granulocytic230 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.origins, which secrete IL6, TGF-b, and other cytokines and,
among other functions, also recruit T helper 17 cells to promote
their immunosuppressive function (Kitamura et al., 2015).
TAMs and TANs are derived from polarized macrophages
and neutrophils respectively, which results in their pro-tumor
phenotypes that facilitate tumor growth and stimulate angiogen-
esis (Lohela et al., 2014; Casbon et al., 2015). In addition, TAMs
promote ECM breakdown, invasion, andmetastasis (reviewed in
Noy and Pollard, 2014; Kitamura et al., 2015). TAMs (and MSCs)
can produce exosomes, enabling ingress of mRNAs and micro-
RNAs (miRNAs) into various cell types (Ratajczak et al., 2006;
Jing et al., 2012) for cancer cell growth and metastasis (Fabbri,
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tumor cells via the transfer of efflux transporters (Jaiswal
et al., 2013). Transformed epithelial cells often undergo epi-
thelial-to-mesenchymal transition (EMT)-like alterations during
which they lose their cellular polarity and cell-cell adhesion and
become mesenchymal like or stem cell like, gaining migratory
and invasive properties (Kalluri and Weinberg, 2009; Karreth
and Tuveson, 2004). In the inflammatory TME, TAMs and CD4+
T cells secrete Tumor necrosis factor alpha (TNFa), which upre-
gulates NF-kB signaling pathways to induce Snail homolog 2
(Slug), Snail homolog 1 (Snail), and Twist family basic helix-
loop-helix transcription factor (Twist) and increase the crosstalk
with the TGF-b signaling pathway which stimulates self-renewal
(Smith et al., 2012; Cabarcas et al., 2011); thus, they can
induce EMT and ultimately promote migration and invasion of
CSCs. The correlation between stemness and EMT implies
that non-CSCs can convert into CSCs through EMT-induced
plasticity.
Hypoxia and Angiogenesis
Perturbed accessibility to vasculature results in hypoxia within
various tumors. This advances stemness through activation of
stem genes and dedifferentiation (Bennewith and Durand,
2004; Brurberg et al., 2006). Hypoxic CSCs impede CD8+
T cell proliferation and activation and inhibit immunosurveil-
lance (Wei et al., 2011). Hypoxia also protects CSCs from
chemotherapy and radiotherapy. Hypoxia further promotes
CSC survival and EMT through reactive oxygen species
(ROS)-activated stress response pathways (Liu et al., 2008)
and through ROS-induced TGF-b and TNF-a signaling path-
ways (Pavlides et al., 2010). Activation of TGF-b as well as
WNT signaling pathways by hypoxia induces stemness by pro-
moting an undifferentiated state in tumor cells (Anido et al.,
2010; Scheel et al., 2011). In various solid cancers, ECs pro-
mote self-renewal of CSCs by direct cell-cell contact or by ni-
tric oxide (NO) production via the NOTCH signaling pathway
(Charles et al., 2010). Hypoxia-inducible factor 1 alpha (HIF-
1a) also can directly increase NOTCH signaling (Quail et al.,
2012). HIF-1a antagonizes Myelocytomatosis viral oncogene
homolog (c-Myc) activation, thus slowing down cell-cycle pro-
gression to protect CSCs from DNA damage and enhance
stemness (Koshiji et al., 2004).
Hypoxia induces CSCs to express hypoxia-inducible factors
(HIFs), which are regulated and stabilized by TGF-b (Cabarcas
et al., 2011). The HIF genes are the primary factors for driving
angiogenesis via induction of VEGF. Under hypoxia, both ECs
and CSCs produce VEGF to stimulate tumor angiogenesis. In
the hypoxic regions of the tumor, VEGF-A can recruit monocytes
and macrophages (Kitamura et al., 2015). A positive correlation
between TAM infiltration and angiogenesis was found in many
human cancers. TAMs become pro-angiogenic through their
response to Macrophage colony stimulating factor (M-CSF) (Lo-
hela et al., 2014), secreted by tumor cells, which induces VEGF-A
production and suppresses anti-angiogenic factor expression.
ECM-Cell Interactions and Cell-Cell Contact
The ECM is an essential noncellular component of the adult
stem cell niche. In solid tumors, increased ECM stiffness
can be a physical barrier blocking therapeutics and thus
protect CSCs from chemotherapeutic agents (Wong and
Rustgi, 2013; Ye et al., 2014). Matrix metalloproteinases(MMPs) that degrade components of ECM in tumors, release
cytokines, growth factors, and other molecules from the
ECM and cell surface (Noe¨l et al., 2012) and facilitate angio-
genesis, tumor cell invasion, and metastasis (Siefert and Sar-
kar, 2012; Kessenbrock et al., 2010). CAFs produce MMP2,
3, and 9 for ECM remodeling, which promotes EMT, enhances
CSC-related marker expression, and exacerbates therapeutic
resistance (Cabarcas et al., 2011). Interestingly, MMPs can
increase WNT signaling and stemness (Kessenbrock et al.,
2013). Increased MMP3 expression facilitates genomic insta-
bility, EMT, and tumor formation, as shown in a mouse model
of breast cancer.
In normal stem cell niches, anchoring stem cells to the niche
through cell-cell contacts is critical to keep them far from differ-
entiation stimuli and physically adjacent to niche factors that
specify self-renewal (Sneddon and Werb, 2007; Borovski et al.,
2011). CSCs also utilize cell-cell contact to preserve their pheno-
type and exert their functions. For example, direct cell contact is
necessary for MSCs to exert their maximal effect on CSCs
(Roorda et al., 2010). Hedgehog and NOTCH signaling pathways
(Gilbertson and Rich, 2007) require cell-cell contact. Notch li-
gands are mostly transmembrane proteins, particularly Jagged
and Delta (Gilbertson and Rich, 2007). Glial cells in the brain
may act as a cell-cell adhesion unit to tether glioma cells (Lin
et al., 2002; Riquelme et al., 2008). In addition, to protect them-
selves from shear forces and NK-cell-mediated lysis, and to
improve their adhesion to endothelium, disseminated cancer
cells surround themselves with platelets, forming a physical
shield (Fessler et al., 2013). Lastly, although there is yet little ev-
idence to support this, the development of cancer might suggest
an enlargement or growth in the size of the niche to accommo-
date numerous CSCs (Shiozawa et al., 2011).
CSCs and Non-CSCs
As inferred above, also CSCs secrete a variety of factors that
help recruit, activate and even create specific cell types to con-
trol the regulation of their differentiation states. Breast CSCs
can produce IL6, which attracts and activates MSCs to produce
the CSC-supportive cytokine CXCL7 (Liu et al., 2011). CSCs
play an important role in TAM recruitment by secreting macro-
phage chemoattractants (Yi et al., 2013). CSCs promote angio-
genesis through HIF-1a and the release of VEGF-A and CXCL12
(Ricci-Vitiani et al., 2010; Borovski et al., 2011). They help
prevent ECs from undergoing hypoxia- or irradiation-induced
apoptosis, resulting in resistance to vascular disrupting agents.
CSCs can produce factors, such as TGF-b, to help transform fi-
broblasts to CAFs (Kalluri and Zeisberg, 2006). MMP10 is highly
expressed in CSCs, correlating with metastasis in many human
tumor types (Jaiswal et al., 2013). Its repression leads to a loss
of stem-cell-related gene expression. Tumor cells, which may
not have CSC characteristics, also take part in the niche and
secrete cytokines and exosomes (Fessler et al., 2013; Ye
et al., 2014).
A bidirectional conversion between CSCs and non-CSCs can
be triggered by an inflammatory stroma, which is characterized
by elevated NF-kB signaling, enhancing Wnt activation, and
inducing dedifferentiation of non-CSCs that acquire tumor-
initiating capacity (Schwitalla et al., 2013). Interestingly, it has
been shown that tumors can be driven by a sub-population of
non-CSCs. These cells that do not have higher fitness, butCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 231
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tumor-promoting microenvironmental changes. Conversely,
the clonal expansion of this non-cell-autonomous driver does
not necessarily translate into increased tumor growth rates.
This driver sub-clone can be outcompeted by a sub-clone with
a higher proliferative yield, thus disintegrating the tumor (Maru-
syk et al., 2014).
CSCs and Metastasis: The Primary TME and the
Metastatic Niche
As summarized below, interactions of CSCs with their niches are
also critical throughout metastatic progression.
CSCs and Metastatic CSCs
Although CSCs may not be the only cells instigating or maintain-
ing metastasis, the CSC-generated hierarchy of stem-like and
differentiated tumor cells is able to initiate metastatic growth
and is also seen in late-stage cancers and atmetastatic sites (Da-
lerba et al., 2011; Merlos-Sua´rez et al., 2011; Vermeulen et al.,
2008). Large-scale genome sequencing studies suggest that pri-
mary tumors accumulate most of the mutations vital to metas-
tasis, showing a predominance of similarity between metastatic
stem cells (MetSCs) and primary CSCs (Yachida et al., 2010).
Gene expression signatures have identified mediators of meta-
static mutations in primary tumors (as stem cell markers) that
correlate with poor prognosis and relapse (Oskarsson et al.,
2014). Cancer cells expressing stem cell markers have been de-
tected in the blood of breast cancer patients; when inoculated
into immunodeficient mice, these cells can generate bone, liver,
and lungmetastases (Baccelli et al., 2013). In addition, analysis of
human colorectal cancer samples using clonal lentiviral marking
demonstrates that metastases arise from primary tumor cells
that display long-term self-renewal capacity and are quiescent
and resistant to chemotherapy (Dieter et al., 2011; Kreso et al.,
2013). Even cancers, such as melanoma, that do not appear to
rely on a hierarchical organization still contain MetSCs (Mea-
chamandMorrison, 2013). Although there is some evidence sug-
gesting that primary tumors and metastases may arise from
different cells (LaBarge, 2010), it could be that MetSCs simply
develop from the original CSCs that evolved throughout tumor
progression due to tumor cell plasticity or generation of MetSCs.
MetSCs may be generated de novo as a result of de novo niche
formation due to competition between cancer and normal stem
cells for niche occupancy (Shiozawa et al., 2011). If MetSCs or
disseminated tumor cells (DTCs) are primary CSCs, many of
the CSC niche considerations will also apply to MetSCs.
The TME Supports Cancer Cell Dissemination
Beyond the passive role of circulation patterns, cancer cell
dissemination is actively influenced by cancer cell autonomous
functions such as invadopodia formation, paracrine factors as
VEGF and Epidermal growth factor (EGF) family members, pro-
teases as MMPs and cathepsins, and recruitment of stromal
components and immunosuppressive cells as TAMs (Oskarsson
et al., 2014). The tumor invasive front is a likely site for selection
of metastatic traits (Cheung et al., 2013). This site is rich with
blood vessels as well as niche cells and factors that support
the survival and fitness of CSCs (Joyce and Pollard, 2009;
Takebe et al., 2011) (Figure 2). Primary tumor stroma also select
for organ-specific seeding traits by releasing exosomes that alter
niche content. In the circulation, transient contact between232 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.platelets and DTCs induces EMT and a CSC-like state (Fessler
et al., 2013). Endothelial tyrosine kinase positive (TIE2+, also
known as CD202B+) macrophages lining the vasculature direct
cancer cell migration along collagen fibers toward higher con-
centrations ofmetastasized cells. Clusters of tumor cells in blood
vessels secrete EGF family members, further directing cancer
cells and macrophages to sites of metastasis (Noy and Pollard,
2014) (Figure 3).
The Metastatic Niche Supports Seeding and Growth of
Metastasis
Circulating tumor cells need the right ‘‘soil’’ in which to seed and
survive, since most metastatic sites are less hospitable than the
origin (Figure 3). The survival and fitness of metastasis-initiating
DTCs depends on specific components of the host environment
that play the part of a niche for these cells, as inferred by
massive CSC loss/apoptosis in colorectal and breast CSCs (Os-
karsson et al., 2014). Although no foreign tissue may be
welcoming to metastatic seeds, certain tissues may be less hos-
tile than others. Similar to the CSC niche, the metastatic niche
designates the specific locations, stromal cell types, diffusible
signals, and ECM proteins that bear consequences for the
metastasis of DTCs (Oskarsson et al., 2014). So beyond cell-
autonomous failures, the inability to metastasize results from
scarcity of survival signals in the host parenchyma, lack of a
supportive stroma, and overexposure to innate immunity
(Chambers et al., 2002; Fidler, 2003; Nguyen et al., 2009;
Schreiber et al., 2011).
Interestingly, the traits required for metastatic dissemination
are distinct from those that mediate overt metastatic coloniza-
tion months or years later. Dormancy is a critical issue for tumor
recurrence and metastatic spread after long lag periods in many
cancers, including breast, melanoma, and leukemia (Pece et al.,
2010; Roesch et al., 2010; Saito et al., 2010). Since dormant cells
are proliferatively quiescent, they survive chemotherapy and
contribute to tumor regrowth, irrespective of genetic differences.
Therefore, understanding the role of the microenvironment in
regulating exit from dormancy is of crucial importance. The
mechanisms of tumor dormancy and the ability of CSCs to
remain quiescent are intertwined with angiogenic dormancy
(Cabarcas et al., 2011). Restricted supplies of nutrients and
oxygen due to poor vascularization cause an arrest in growth
(Almog, 2010), which can also potentially result from the absence
of necessary factors required by CSCs to reinitiate tumor forma-
tion or metastasis. Although angiogenic stimulators such as
c-Myc, VEGF, and Fibroblast growth factor 2 (FGF-2) (Shachaf
et al., 2004; Naumov et al., 2006) may play a role in mediating tu-
mor exit from dormancy.
Although DTCs in bone marrow appear dormant, the overall
DTC population is not static (Mu¨ller et al., 2005; Pantel et al.,
1993). DTCs may constantly transition between dormant and
active states during metastatic latency, being further selected
for colonization functionality. Circulating metastatic cells co-ex-
press EMT and stemmarkers (Plaks et al., 2013b). Although EMT
enables migration, it interferes with proliferation and metastatic
growth (Ocan˜a et al., 2012; Stankic et al., 2013). Thus, MetSCs
that have undergone EMT may need to reacquire an epithelial
phenotype to seed and resume growth at the metastatic site.
This reverse process is called mesenchymal-to-epithelial tran-
sition (MET) (Tsai et al., 2012; Ocan˜a et al., 2012; Gupta et al.,
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extravasation, by a yet-unknown mechanism. Despite the clin-
ical importance of metastatic latency, mouse models lack a
prolonged dormancy of MetSCs and xenograft assays may
either restrict CSC detection to only the most robustly prolifer-
ating cells (Quintana et al., 2008), since they are read within
months after transplantation or activate dormant cells by serial
transplantation. Therefore, little is known about entering and
exiting dormancy, forms of dormancy, and signaling during
dormancy, and it remains an overarching challenge for success-
fully combating many cancers, so better models are needed
(Kreso et al., 2013).
Metastatic Seeding Occurs in a Variety of Niches
DTCs may occupy normal stem cell niches in the host tissues
(Figure 3). MSCs produce TGF-b family molecules, CXCL12,
and Hedgehog signals in the bone marrow for hematopoietic
stem cell maintenance while metastatic cancer cells from other
sites occupy this niche to benefit from cues that enhance stem
cell properties and deter differentiation (Shiozawa et al., 2011).
The cognate chemokine receptor CXCR4 is frequently overex-
pressed in bone metastatic cells and provides CSCs with
chemotaxis and Phosphoinositide 3-kinase (PI3K)-mediated
survival signals that mediate oncogenic transformation (Mu¨ller
et al., 2001; Zlotnik et al., 2011).
DTCs initiate metastatic outgrowth around blood capillaries, in
perivascular niches (Figure 3). These may support MetSCs by
supplying attachment, oxygen, nutrients, and paracrine factors
from the activated endothelium (Butler et al., 2010; Fessler
et al., 2013). The perivascular niche is a preferred residence for
glioma CSCs that supplies them with Hedgehog-, NOTCH-,
and PI3K-activating signals. Breast cancer, lung cancer, and
melanoma cells that infiltrate the brain surround capillaries and
some stretch themselves over the perivascular basal lamina
(Charles and Holland, 2010; Hambardzumyan et al., 2008).
DTCs seed metastasis in distant tissue niches (Figure 3). In
mouse models, breast, lung, and gastrointestinal tumors estab-
lish premetastatic niches by secreting systemic factors such as
VEGF-A, TGF-b, Granulocyte colony-stimulating factor (G-CSF),
TNF, and lysyl oxidase (LOX) that induce expression of chemo-
tactic proteins (S100 calcium binding protein A8, A9 [S100A8,
S100A9], and serum amyloid A3 [SAA3]), ECM-remodeling en-
zymes, and exosomes into the circulation and directs various
cells to induce pro-metastatic changes in the lung parenchyma
microenvironment before DTCs arrive (Oskarsson et al., 2014;
Kaplan et al., 2005; Hiratsuka et al., 2006; Casbon et al., 2015).
Primary tumors induce recruitment andmobilization of VEGFR1+
bone-marrow-derived hematopoietic progenitor cells (HPCs)
before the arrival of tumor cells (Kaplan et al., 2005). Pre-existing
fibroblasts increase fibronectin deposition in these sites, which
binds and clusters HPCs, and fibroblasts induce remodeling of
stroma (Olaso et al., 1997). Macrophages, activated neutrophils,
and Tregs are also recruited to the niche to promote future
metastasis. Neutrophils could also potentially enhance MetSC
settlement by producing neutrophil extracellular traps (NETs)
(Casbon et al., 2015; Cools-Lartigue et al., 2013; Kitamura
et al., 2015). The metastatic niches are populated by Gr1+
CD11b+ myeloid cells recruited by LOX and S100A proteins
(Erler et al., 2009; Psaila and Lyden, 2009; Yan et al., 2010). How-
ever, direct evidence showing a pro-metastatic role for thesemyeloid cells through immunosuppression is lacking, even
though CD11b+Gr1+ and CD11b+Ly6G+ cells promote metasta-
tic processes (Yang et al., 2010; Casbon et al., 2015). The ECM
component tenascin C (TNC) is found in stem cell niches,
frequently supplied by CAFs and associated with increased
risk of metastasis (Oskarsson et al., 2011). TNC regulates Musa-
shi and other factors to enhance NOTCH and WNT signaling to
support CSCs.
Once metastatic cells arrive, they continue to remodel their
microenvironment. Breast CSCs induce the expression of the
ECM molecule periostin in lung fibroblasts that binds WNT li-
gands to helpmaintain stemness of arriving CSCs. Asmetastatic
lesions grow, the cancer cells recruit TAMs, myeloid precursors,
and mesenchymal cells that establish paracrine loops feeding
back to the cancer cells with various survival and self-renewal
factors (Kitamura et al., 2015). In osteolytic bone metastasis of
breast cancer, osteoclasts resorb bone matrix to make room
for the metastatic growth and release TGF-b and other growth
factors. These factors stimulate cancer cells in a feed-forward
cycle of tissue destruction and metastatic expansion (Ell and
Kang, 2012; Weilbaecher et al., 2011). The metastatic cells
also trigger angiogenesis, and the newly forming blood vessels
attract more MetSCs by expressing fibronectin and Vascular
cell adhesion molecule (VCAM) (Fessler et al., 2013). These
MetSCs produce CCL2 and attract CCR2+ inflammatory mono-
cytes that become metastatic-associated macrophages and
support metastatic growth (Kitamura et al., 2015).
Interestingly, in models of brain metastasis from breast and
lung cancers, brain stroma takes an active role in killing the infil-
trating cancer cells (Valiente et al., 2014). However, little is known
about what kills the majority of DTCs. More information on how
the reactive stroma repels DTCs could yield clues for how to
leverage these mechanisms for therapeutic benefit.
The Stem Cell Niche as a Target for Cancer Therapy
Generally, CSCs appear to be resistant to conventional cancer
therapies such as ionizing radiation and conventional anti-pro-
liferative chemotherapy due to their quiescence (Bao et al.,
2006; Li et al., 2008). On the other hand, CSCs can be more
sensitive to some therapies as compared to non-tumorigenic
cells. Rapamycin treatment in a mouse model of leukemia
induced by conditional Phosphatidylinositol-3,4,5-trisphos-
phate 3-phosphatase (Pten) deletion in hematopoietic cells
causes the depletion of leukemia-initiating cells and restores
normal hematopoietic stem cell function. Although the histolog-
ical evidence of leukemia persisted, the mice were overtly
healthy (Yilmaz et al., 2006). Radiation or cisplatin therapy
may preferably target the undifferentiated cells that drive testic-
ular germ cell tumors (Clevers, 2011). Differentiation therapies
that specifically target CSCs by exploiting their capacity to
differentiate can be effective in some cases (Meacham and
Morrison, 2013). This strategy is successful in inducing cell-cy-
cle progression in acute myeloid leukemia stem cells by sup-
plying G-CSF to promote sensitivity to chemotherapy (Saito
et al., 2010). Similarly, mouse glioblastoma stem cells can be
induced to differentiate into glia by treatment with the protein
BMP4, resulting in reduced proliferation, tumor growth, and tu-
mor-initiation capability of CSCs upon transplantation (Lom-
bardo et al., 2011; Piccirillo et al., 2006).Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 233
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ment of targeted cancer therapies, as tumor cell populations are
continually evolving and therapeutic eradication of existing CSC
populations might be followed by their regeneration from non-
CSCs within the tumor under treatment (Chaffer and Weinberg,
2015). In addition, most stem cell markers used to date are not
good targets for antibody therapy. Moreover, many of these
markers, especially in solid tumors, fail to distinguish normal
stem cells from CSCs. High-throughput screening could be an
unbiased approach to uncover known or new compounds that
specifically target CSCs (Clevers, 2011).
An Alternative Strategy: Targeting the Unique Aberrant
Microenvironment of CSCs
Since the TME has the potential to support and initiate stem
cell-like programs in cancer cells, targeting CSC niche factors
that regulate plasticity may prove to be a more powerful modal-
ity for the treatment and prevention of tumor cell plasticity and
progression than targeting the CSCs directly. However, it
should equally be taken into account that in a particular cancer
type/stage, CSCs may evolve to escape niche constraints and
become independent of niches. Therefore, targeting the niche
may be a critical aspect of effective cancer therapy in systems
where the aberrant activation of the pathway that is about to be
targeted is regulating CSCs at the cell surface level rather than
a cell-autonomous mutation, which provides independence
from growth factors or abolishes an apoptotic response to drive
clonal expansions (Clevers, 2011). In cases where tumor pro-
gression is limited by microenvironmental constraints that
cannot be overcome by a cell-autonomous increase in prolifer-
ation rates, it is possible that these secreted factors not only
preferentially benefit the CSCs, enabling their clonal domi-
nance, but also actually mediate inter-clonal interactions that
could also be drivers of the tumor (Marusyk et al., 2012). Over-
all, it seems that the niche has a differential importance de-
pending on the cancer type and even on the specific stage of
that particular cancer. Experimental analysis and clinical diag-
nostics still need to take place in order to elucidate such mech-
anisms in various cancers.
Some attempts to target the niche has already show promise.
Antibodies that abrogate the activation of c-Met by HGF signifi-
cantly inhibit xenograft growth of colon tumors (Hoey et al.,
2009). Fibronectin and hyaluronic acid facilitate a quiescent state
in some cancer cells when they are under siege from chemo-
therapy. Indeed, antibodies against the fibronectin receptor
a4b1 integrin prevent association of tumor cells with metastatic
niches (Kaplan et al., 2005). Targeting MMPs is likely to be more
effective in early-stage tumors that are more dependent on their
activity than late-stage, established tumors, and the effect on
CSCs should be investigated (Kessenbrock et al., 2010). Target-
ing hypoxia is another attempt to manipulate a niche of quies-
cent, drug-resistant cells. HIF-1a and HIF-2a, which promote
cell cycle via c-Myc, represent a promising target for therapy
for glioma patients (Gordan et al., 2007; Li et al., 2009). Various
angiogenic inhibitors have shown positive results in various can-
cers. Anti-angiogenic therapy targeting VEGF can deplete the tu-
mor vasculature and ablate self-renewing CSCs (Ye et al., 2014),
thus inhibiting tumor growth. Interfering with tumor EC growth
and survival could inhibit not only angiogenesis but also the
self-replication of CSCs (Gu et al., 2012).234 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.A successful approach in combating tumors is targeting im-
mune checkpoints by either blocking immunosuppressive
mechanisms to restore T cell function (such as Programmed
cell death 1 [PD1] and its ligand PDL1) or enhancing immune
function by engaging co-stimulatory receptors such as Tumor
necrosis factor receptor superfamily member 4 (OX40) with
agonist antibodies. Most successful is the use of a monoclonal
antibody targeting the negative immune checkpoint protein
Cytotoxic T-lymphocyte-associated protein (CTLA-4) (Junttila
and de Sauvage, 2013). Other technologies that are currently
in clinical development attempt to directly engage T-cell-medi-
ated killing. Adoptive cell-transfer therapy, which involves the
ex vivo expansion and reinfusion of tumor-reactive T cells, is
emerging as a potential curative treatment for patients with
advanced-stage cancer (Klebanoff et al., 2012). Overall, immu-
notherapy is an emerging field, and the exact mechanism by
which these therapies may abrogate the ability of CSCs to reini-
tiate tumors is still under investigation.
Combinatorial treatment with conventional cancer therapies
may be an effective strategy. Interferon gamma (IFN-g) shows
synergistic effects with the conventional anticancer drug oxali-
platin to eliminate both CSCs and differentiated cancer cells in
colorectal cancer (Ni and Huang, 2013). Depletion of TAMs or
IMs by inhibiting either CCR2 or M-CSF receptor resulted in
decreased CSCs in pancreatic tumors, improved chemothera-
peutic efficacy, inhibited metastasis, and increased antitumor
T cell responses (Mitchem et al., 2013). Targeting components
of the innate immune system along with conventional therapy is
also under clinical evaluation. For example, the anti-CD40
agonist antibody and gemcitabine combination therapy has
shown early clinical promise in treating pancreatic cancer
(Junttila and de Sauvage, 2013). Targeting the bulk of the tumor
with standard cancer therapy could help remodel the CSCs
niche, exposing crucial niche component(s) and making it
more receptive to niche-targeted therapeutics. For example,
using conventional cancer therapeutics to expose anti-tumor
DCs to antigens that are otherwise inaccessible to them (Broz
et al., 2014) with a combination of immunotherapy using engi-
neered DCs with enhance ability to stimulate T-cell-mediated
tumor rejection could potentially be a successful strategy to
eradicate CSCs.
Concluding Remarks
It is now accepted that most cancers originate from cells that
gained tumor-initiating capacity and that these cells are plas-
tic in nature. The tumor-initiating capacity or cancer stemness
of these cells could therefore be influenced by extrinsic fac-
tors. It is also postulated that in many cancers the TME and
especially the closely related niches have detrimental effects
on the ability of these cells to initiate a tumor and/or metasta-
size. Due to their plasticity and given that CSCs need to be
eradicated to prevent malignancy and metastasis, targeting
specific niche components relevant to that particular cancer
type in addition to standard cancer therapy that tackles the
bulk of the tumor bears therapeutic promise. A better under-
standing of CSC biology and niche factors of each cancer
subtype as well as their modulation using various therapeutic
designs is paramount for this paradigm to be fully applicable
in the clinic.
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